Personalizing medicine for metastatic colorectal cancer: Current developments

World Journal of Gastroenterology

Volumn 20, Issue 30, 2014, Pages 10425-10431

  Marques, Andrea Marin ^a   Turner, Alice ^b   De Mello, Ramon Andrade ^c,d  

^a Centro Hospitalar Do Médio Ave   (Portugal)

^b UNIVERSITY OF OTAGO   (New Zealand)

^c PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^d UNIVERSITY OF ALGARVE   (Portugal)

Author keywords

Angiogenesis; Epidermal growth factor; Metastatic colorectal cancer; Target therapy; Vascular endothelial growth factor

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; BRIVANIB; CAPECITABINE PLUS OXALIPLATIN; CEDIRANIB; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PANITUMUMAB; REGORAFENIB; SEMAXANIB; SUNITINIB; VASCULOTROPIN ANTIBODY; VASCULOTROPIN INHIBITOR; VATALANIB; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; TUMOR MARKER;

ADVANCED CANCER; ANGIOGENESIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL STUDY; HUMAN; METASTATIC COLORECTAL CANCER; MOLECULARLY TARGETED THERAPY; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); SURVIVAL TIME; TUMOR VASCULARIZATION; COLORECTAL NEOPLASMS; DRUG EFFECTS; GENETIC PREDISPOSITION; GENETICS; METASTASIS; MORTALITY; PATHOLOGY; PHENOTYPE; PREDICTIVE VALUE; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; COLORECTAL NEOPLASMS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; PHENOTYPE; PRECISION MEDICINE; PREDICTIVE VALUE OF TESTS; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 84920593825     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i30.10425     Document Type: Article

References (48)

1. Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, Cooper D, Gansler T, Lerro C, Fedewa S, Lin C, Leach C, Cannady RS, Cho H, Scoppa S, Hachey M, Kirch R, Jemal A, Ward E. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 2012; 62: 220-241 [PMID: 22700443 DOI: 10.3322/caac.21149]
2. Van Cutsem E, Nordlinger B, Adam R, Köhne CH, Pozzo C, Poston G, Ychou M, Rougier P. Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. Eur J Cancer 2006; 42: 2212-2221 [PMID: 16904315 DOI: 10.1016/j.ejca.2006.04.012]
3. Muratore A, Zorzi D, Bouzari H, Amisano M, Massucco P, Sperti E, Capussotti L. Asymptomatic colorectal cancer with un-resectable liver metastases: immediate colorectal resection or up-front systemic chemotherapy? Ann Surg Oncol 2007; 14: 766-770 [PMID: 17103261 DOI: 10.1245/s10434-006-9146-1]
4. Midgley R, Kerr D. Conventional cytotoxic and novel therapeutic concepts in colorectal cancer. Expert Opin Investig Drugs 2001; 10: 1011-1019 [PMID: 11772231 DOI: 10.1517/13 543784.10.6.1011]
5. Cercek A, Saltz L. Evolving treatment of advanced colorectal cancer. Curr Oncol Rep 2010; 12: 153-159 [PMID: 20425074 DOI: 10.1007/s11912-010-0096-1]
6. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E. Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer. N Engl J Med 2004; 351: 337-345 [PMID: 15269313 DOI: 10.1056/NEJMoa033025]
7. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342 [PMID: 15175435 DOI: 10.1056/NEJMoa032691]
8. Laurent-Puig P, Cayre A, Manceau G, Buc E, Bachet JB, Lecomte T, Rougier P, Lievre A, Landi B, Boige V, Ducreux M, Ychou M, Bibeau F, Bouché O, Reid J, Stone S, Penault-Llorca F. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol 2009; 27: 5924-5930 [PMID: 19884556 DOI: 10.1200/JCO.2008.21.6796]
9. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005; 307: 58-62 [PMID: 15637262 DOI: 10.1126/science.1104819]
10. Sun W. Angiogenesis in metastatic colorectal cancer and the benefits of targeted therapy. J Hematol Oncol 2012; 5: 63 [PMID: 23057939 DOI: 10.1186/1756-8722-5-63]
11. Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002; 20: 4368-4380 [PMID: 12409337 DOI: 10.1200/JCO.2002.10.088]
12. Choong HL, Pwee HS, Woo KT, Lim CH. Maintenance haemodialysis in Singapore. Singapore Med J 1991; 32: 133-138 [PMID: 1876882 DOI: 10.1016/S0002-9440(10)65006-7]
13. Padera TP, Stoll BR, Tooredman JB, Capen D, di Tomaso E, Jain RK. Pathology: cancer cells compress intratumour vessels. Nature 2004; 427: 695 [PMID: 14973470 DOI: 10.1038/427695a]
14. Boucher Y, Baxter LT, Jain RK. Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: implications for therapy. Cancer Res 1990; 50: 4478-4484 [PMID: 2369726]
15. Fukumura D, Duda DG, Munn LL, Jain RK. Tumor microvasculature and microenvironment: novel insights through intravital imaging in pre-clinical models. Microcirculation 2010; 17: 206-225 [PMID: 20374484 DOI: 10.1111/j.1549-8719.2010.00029. x]
16. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L, Rougier P. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355: 1041-1047 [PMID: 10744089 DOI: 10.1016/S0140-6736(00)02034-1]
17. Cassidy J, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzén F, Saltz L. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 2008; 26: 2006-2012 [PMID: 18421053 DOI: 10.1200/jco.2007.14.9898]
18. Falcone A, Ricci S, Brunetti I, Pfanner E, Allegrini G, Barbara C, Crinò L, Benedetti G, Evangelista W, Fanchini L, Cortesi E, Picone V, Vitello S, Chiara S, Granetto C, Porcile G, Fioretto L, Orlandini C, Andreuccetti M, Masi G. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 2007; 25: 1670-1676 [PMID: 17470860 DOI: 10.1200/jco.2006.09.0928]
19. Grothey A, Sargent D, Goldberg RM, Schmoll HJ. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004; 22: 1209-1214 [PMID: 15051767 DOI: 10.1200/jco.2004.11.037]
20. Saif MW. Is there a benefit from addiction to anti-VEGF therapy in patients with colorectal cancer? Anticancer Res 2013; 33: 2377-2380 [PMID: 23749885]
21. Bennouna J, Sastre J, Arnold D, Österlund P, Greil R, Van Cutsem E, von Moos R, Viéitez JM, Bouché O, Borg C, Steffens CC, Alonso-Orduña V, Schlichting C, Reyes-Rivera I, Bendahmane B, André T, Kubicka S. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol 2013; 14: 29-37 [PMID: 23168366 DOI: 10.1016/S1470-2045(12)70477-1]
22. Haraldsdottir S, Bekaii-Saab T. Integrating anti-EGFR therapies in metastatic colorectal cancer. J Gastrointest Oncol 2013; 4: 285-298 [PMID: 23997940]
23. Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D'Haens G, Pintér T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J, Rougier P. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360: 1408-1417 [PMID: 19339720 DOI: 10.1056/NEJMoa0805019]
24. Jain RK, Duda DG, Clark JW, Loeffler JS. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 2006; 3: 24-40 [PMID: 16407877]
25. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004; 3: 391-400 [PMID: 15136787]
26. Cohen MH, Gootenberg J, Keegan P, Pazdur R. FDA drug approval summary: bevacizumab plus FOLFOX4 as secondline treatment of colorectal cancer. Oncologist 2007; 12: 356-361 [PMID: 17405901 DOI: 10.1634/theoncologist.12-3-356]
27. Tabernero J, Van Cutsem E, Lakomý R, Prausová J, Ruff P, van Hazel GA, Moiseyenko VM, Ferry DR, McKendrick JJ, Soussan-Lazard K, Chevalier S, Allegra CJ. Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial. Eur J Cancer 2014; 50: 320-331 [PMID: 24140268 DOI: 10.1016/j.ejca.2013.09.013]
28. Chung C, Pherwani N. Ziv-aflibercept: a novel angiogenesis inhibitor for the treatment of metastatic colorectal cancer. Am J Health Syst Pharm 2013; 70: 1887-1896 [PMID: 24128964 DOI: 10.2146/ajhp130143]
29. Menon RS, Rusinko MS, Allen PS. Proton relaxation studies of water compartmentalization in a model neurological system. Magn Reson Med 1992; 28: 264-274 [PMID: 1281258 DOI: 10.1002/mrm.1910280208]
30. Clarke JM, Hurwitz HI. Understanding and targeting resistance to anti-angiogenic therapies. J Gastroint Oncol 2013; 4: 253-263 [PMID: 23997938 DOI: 10.3978/j.issn.2078-6891.2013. 036]
31. Ciombor KK, Berlin J, Chan E. Aflibercept. Clin Cancer Res 2013; 19: 1920-1925 [PMID: 23444216 DOI: 10.1158/1078-0432. ccr-12-2911]
32. Chu QS. Aflibercept (AVE0005): an alternative strategy for inhibiting tumour angiogenesis by vascular endothelial growth factors. Expert Opin Biol Ther 2009; 9: 263-271 [PMID: 19236257 DOI: 10.1517/14712590802666397]
33. Van Cutsem E, Tabernero J, Lakomy R, Prenen H, Prausová J, Macarulla T, Ruff P, van Hazel GA, Moiseyenko V, Ferry D, McKendrick J, Polikoff J, Tellier A, Castan R, Allegra C. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 2012; 30: 3499-3506 [PMID: 22949147 DOI: 10.1200/jco.2012.42.8201]
34. Lockhart AC, Rothenberg ML, Dupont J, Cooper W, Chevalier P, Sternas L, Buzenet G, Koehler E, Sosman JA, Schwartz LH, Gultekin DH, Koutcher JA, Donnelly EF, Andal R, Dancy I, Spriggs DR, Tew WP. Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors. J Clin Oncol 2010; 28: 207-214 [PMID: 19949018 DOI: 10.1200/JCO.2009.22.9237]
35. O'Farrell AM, Abrams TJ, Yuen HA, Ngai TJ, Louie SG, Yee KW, Wong LM, Hong W, Lee LB, Town A, Smolich BD, Manning WC, Murray LJ, Heinrich MC, Cherrington JM. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003; 101: 3597-3605 [PMID: 12531805 DOI: 10.1182/blood-2002-07-2307]
36. Carrato A, Swieboda-Sadlej A, Staszewska-Skurczynska M, Lim R, Roman L, Shparyk Y, Bondarenko I, Jonker DJ, Sun Y, De la Cruz JA, Williams JA, Korytowsky B, Christensen JG, Lin X, Tursi JM, Lechuga MJ, Van Cutsem E. Fluorouracil, leucovorin, and irinotecan plus either sunitinib or placebo in metastatic colorectal cancer: a randomized, phase III trial. J Clin Oncol 2013; 31: 1341-1347 [PMID: 23358972 DOI: 10.1200/jco.2012.45.1930]
37. Wood JM, Bold G, Buchdunger E, Cozens R, Ferrari S, Frei J, Hofmann F, Mestan J, Mett H, O'Reilly T, Persohn E, Rösel J, Schnell C, Stover D, Theuer A, Towbin H, Wenger F, Woods-Cook K, Menrad A, Siemeister G, Schirner M, Thierauch KH, Schneider MR, Drevs J, Martiny-Baron G, Totzke F. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 2000; 60: 2178-2189 [PMID: 10786682]
38. Abstracts of the 41st Annual Meeting of the American Society of Clinical Oncology (ASCO). May 13-17, 2005. Orlando, Florida, USA. J Clin Oncol 2005; 23: 1s-1087s [PMID: 15957209]
39. Van Cutsem E, Bajetta E, Valle J, Köhne CH, Hecht JR, Moore M, Germond C, Berg W, Chen BL, Jalava T, Lebwohl D, Meinhardt G, Laurent D, Lin E. Randomized, placebocontrolled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787/ZK 222584 in patients with previously treated metastatic colorectal adenocarcinoma. J Clin Oncol 2011; 29: 2004-2010 [PMID: 21464401 DOI: 10.1200/jco.2010.29.5436]
40. Kohne C, Bajetta E, Lin E. Final results of CONFIRM 2: A multinational, randomized, double-blind, phase III study in 2nd line patients (pts) with metastatic colorectal cancer (mCRC) receiving FOLFOX4 and PTK787/ZK 222584 (PTK/ZK) or placebo. J Clin Oncol 2007; 25 (Suppl 18S): 4033
41. Fong TA, Shawver LK, Sun L, Tang C, App H, Powell TJ, Kim YH, Schreck R, Wang X, Risau W, Ullrich A, Hirth KP, McMahon G. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 1999; 59: 99-106 [PMID: 9892193]
42. Hoff PM, Wolff RA, Bogaard K, Waldrum S, Abbruzzese JL. A Phase I study of escalating doses of the tyrosine kinase inhibitor semaxanib (SU5416) in combination with irinotecan in patients with advanced colorectal carcinoma. Jpn J Clin Oncol 2006; 36: 100-103 [PMID: 16449240 DOI: 10.1093/jjco/hyi229]
43. Kies M, Blumenschein GJ, Christensen O. Phase I study of regorafenib (BAY 73-4506), an inhibitor of oncogenic and angiogenic kinases, administered continuously in patients (pts) with advanced refractory non-small cell lung cancer (NSCLC). J Clin Oncol 2010; 28 (15 Suppl): 7585
44. Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, Humblet Y, Bouché O, Mineur L, Barone C, Adenis A, Tabernero J, Yoshino T, Lenz HJ, Goldberg RM, Sargent DJ, Cihon F, Cupit L, Wagner A, Laurent D. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013; 381: 303-312 [PMID: 23177514 DOI: 10.1016/S0140-6736(12)61900-X]
45. Cai ZW, Zhang Y, Borzilleri RM, Qian L, Barbosa S, Wei D, Zheng X, Wu L, Fan J, Shi Z, Wautlet BS, Mortillo S, Jeyaseelan R, Kukral DW, Kamath A, Marathe P, D'Arienzo C, Derbin G, Barrish JC, Robl JA, Hunt JT, Lombardo LJ, Fargnoli J, Bhide RS. Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2, 1-f][1, 2, 4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (BMS-540215). J Med Chem 2008; 51: 1976-1980 [PMID: 18288793 DOI: 10.1021/jm7013309]
46. Lieu C, Heymach J, Overman M, Tran H, Kopetz S. Beyond VEGF: inhibition of the fibroblast growth factor pathway and antiangiogenesis. Clin Cancer Res 2011; 17: 6130-6139 [PMID: 21953501 DOI: 10.1158/1078-0432.ccr-11-0659]
47. Siu LL, Shapiro JD, Jonker DJ, Karapetis CS, Zalcberg JR, Simes J, Couture F, Moore MJ, Price TJ, Siddiqui J, Nott LM, Charpentier D, Liauw W, Sawyer MB, Jefford M, Magoski NM, Haydon A, Walters I, Ringash J, Tu D, O'Callaghan CJ. Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: the NCIC Clinical Trials Group and AGITG CO.20 Trial. J Clin Oncol 2013; 31: 2477-2484 [PMID: 23690424 DOI: 10.1200/jco.2012.46.0543]
48. Schmoll HJ, Cunningham D, Sobrero A, Karapetis CS, Rougier P, Koski SL, Kocakova I, Bondarenko I, Bodoky G, Mainwaring P, Salazar R, Barker P, Mookerjee B, Robertson J, Van Cutsem E. Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III). J Clin Oncol 2012; 30: 3588-3595 [PMID: 22965961 DOI: 10.1200/jco.2012.42.5355]